SCYNEXIS (SCYX) 10-K 29 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 01, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	SCYNEXIS, Inc.
Trading Symbol	SCYX
Entity Central Index Key	0001178253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		20,622,778
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
ICFR Auditor Attestation Flag	false
Entity Public Float			$ 77,935,551
Entity Interactive Data Current	Yes
Entity File Number	001-36365
Entity Tax Identification Number	56-2181648
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1 Evertrust Plaza
Entity Address, Address Line Two	13th Floor
Entity Address, City or Town	Jersey City
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07302 - 6548
City Area Code	201
Local Phone Number	884-5485
Document Transition Report	false
Title of Each Class	Common Stock, par value $0.001 per share
Name of Each Exchange on Which Registered	NASDAQ
Document Annual Report	true
Documents Incorporated by Reference	Documents Incorporated by Reference Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2020.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 93,041	$ 41,920
Short-term investments		6,494
Prepaid expenses and other current assets	5,165	3,988
Total current assets	98,206	52,402
Other assets	573	812
Deferred offering costs	187	70
Restricted cash	273	273
Property and equipment, net	298	405
Operating lease right-of-use asset (Note 8)	2,999	3,191
Total assets	102,536	57,153
Current liabilities:
Accounts payable	4,639	7,177
Accrued expenses	4,141	3,801
Warrant liabilities	17,564
Operating lease liability, current portion (Note 8)	52	36
Total current liabilities	26,396	11,014
Warrant liabilities	33,592	18,396
Convertible debt and derivative liabilities (Note 7)	16,516	11,522
Operating lease liability (Note 8)	3,274	3,326
Total liabilities	79,778	44,258
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of December 31, 2020 and December 31, 2019	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020, and December 31, 2019; 19,663,698 and 9,741,372 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively	20	10
Additional paid-in capital	349,351	284,313
Accumulated deficit	(326,613)	(271,428)
Total stockholders’ equity	22,758	12,895
Total liabilities and stockholders’ equity	$ 102,536	$ 57,153

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Jul. 17, 2020	Jul. 16, 2020	Dec. 31, 2019	Jun. 18, 2019	Jun. 17, 2019	May 07, 2014
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001			$ 0.001			$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000			5,000,000			5,000,000
Preferred stock, shares issued (in shares)	0			0
Preferred stock, shares outstanding (in shares)	0			0
Common stock, par value (in dollars per share)	$ 0.001			$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000	250,000,000	100,000,000	250,000,000	125,000,000
Common stock, shares issued (in shares)	19,663,698	10,508,302	105,083,291	9,741,372
Common stock, shares outstanding (in shares)	19,663,698	10,508,302	105,083,291	9,741,372

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 0	$ 121
Operating expenses:
Research and development	36,522	38,394
Selling, general and administrative	14,627	10,648
Total operating expenses	51,149	49,042
Loss from operations	(51,149)	(48,921)
Other expense (income):
Loss on extinguishment of debt	1,766	1,045
Amortization of debt issuance costs and discount	1,201	1,171
Interest income	(189)	(805)
Interest expense	1,181	986
Other income	(334)	(538)
Other expense	602	0
Warrant liabilities fair value adjustment	5,214	4,497
Derivative liability fair value adjustment	(2,257)	(1,567)
Total other expense:	7,184	4,789
Loss before taxes	(58,333)	(53,710)
Income tax benefit	3,148	0
Net loss	$ (55,185)	$ (53,710)
Net loss per share – basic and diluted	$ (5.15)	$ (9.58)
Weighted average common shares outstanding – basic and diluted	10,720,211	5,608,138

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance at Dec. 31, 2018	$ 31,225	$ 5	$ 248,938	$ (217,718)
Beginning balance (in shares) at Dec. 31, 2018		4,797,198
Net loss	(53,710)			(53,710)
Stock-based compensation expense	1,828		1,828
Common stock issued through employee stock purchase and stock option plans	37		37
Common stock issued through employee stock purchase plan and stock option plan (in shares)		3,684
Common stock issued, net of expenses	30,530	$ 5	30,525
Common stock issued, net of expenses (in shares)		4,773,692
Common stock issued for conversion	2,984		2,984
Common stock issued for conversion of Notes (in shares)		162,600
Common stock issued for exercise of stock options	12		12
Common stock issued for exercise of stock options (in shares)		2,252
Common stock issued for vested restricted stock units	(11)		(11)
Common stock issued for vested restricted stock units (in shares)		1,946
Ending balance at Dec. 31, 2019	$ 12,895	$ 10	284,313	(271,428)
Ending balance (in shares) at Dec. 31, 2019	9,741,372	9,741,372
Net loss	$ (55,185)			(55,185)
Stock-based compensation expense	2,220		2,220
Common stock issued through employee stock purchase and stock option plans	28		28
Common stock issued through employee stock purchase plan and stock option plan (in shares)		4,652
Common stock issued, net of expenses	57,184	$ 9	57,175
Common stock issued, net of expenses (in shares)		9,156,304
Common stock issued for conversion	$ 5,222	$ 1	5,221
Common stock issued for conversion of Notes (in shares)		638,809
Common stock issued for exercise of stock options (in shares)	166
Common stock issued for Commitment Shares	$ 602		602
Common stock issued for Commitment Shares (in shares)		70,910
Common stock issued for vested restricted stock units	(208)		(208)
Common stock issued for vested restricted stock units (in shares)		51,651
Ending balance at Dec. 31, 2020	$ 22,758	$ 20	$ 349,351	$ (326,613)
Ending balance (in shares) at Dec. 31, 2020	19,663,698	19,663,698

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (55,185)	$ (53,710)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	111	111
Stock-based compensation expense	2,220	1,828
Accretion of investment discount	0	(16)
Amortization of debt issuance costs and discount	1,201	1,171
Warrant liabilities fair value adjustment	5,214	4,497
Derivative liability fair value adjustment	(2,257)	(1,567)
Noncash operating lease expense for right-of-use asset	192	174
Loss on extinguishment of debt	1,766	1,045
Noncash consideration associated with common stock purchase agreement	602	0
Changes in operating assets and liabilities:
Prepaid expenses, other assets, and deferred costs	(922)	3,254
Accounts payable and accrued expenses	(2,296)	5,215
Deferred revenue	0	(121)
Net cash used in operating activities	(49,354)	(38,119)
Cash flows from investing activities:
Maturities of investments	20,713	65,740
Purchases of property and equipment	(4)	0
Purchase of investments	(14,235)	(39,500)
Net cash provided by investing activities	6,474	26,240
Cash flows from financing activities:
Proceeds from common stock issued	90,554	46,337
Payments of offering costs and underwriting discounts and commissions	(5,879)	(2,855)
Proceeds from employee stock purchase plan issuances	28	49
Repurchase of shares to satisfy tax withholdings	(208)	0
Proceeds from senior convertible notes	10,000	16,000
Payments of senior convertible notes issuance costs	(494)	(1,253)
Payment of loan payable expected to be refinanced	0	(15,973)
Net cash provided by financing activities	94,001	42,305
Net increase in cash, cash equivalents, and restricted cash	51,121	30,426
Cash, cash equivalents, and restricted cash at beginning of period	42,193	11,767
Cash, cash equivalents, and restricted cash at end of period	93,314	42,193
Supplemental cash flow information:
Cash paid for interest	1,088	850
Cash received for interest	186	898
Noncash financing and investing activities:
Operating lease liabilities arising from obtaining right-of-use assets	0	3,365
Deferred offering and issuance costs included in accounts payable	62	0
Deferred offering costs reclassified to additional paid-in capital	153	36
Common stock issued for settlement of senior convertible notes	5,221	2,984
Common stock issued for Commitment Shares	$ 602	$ 0

Description of Business and Bas

Description of Business and Basis of Preparation	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Preparation	1 . Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its lead product candidate, ibrexafungerp, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $326.6 million at December 31, 2020 and limited capital resources to fund ongoing operations. These capital resources primarily comprised cash and cash equivalents of $93.0 million at December 31, 2020. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying consolidated financial statements, the Company's liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to potentially commercialize ibrexafungerp for the treatment of vaginal yeast infections and; (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Company’s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation. Shelf Registration Filings On December 31, 2020 and September 11, 2020, the Company filed shelf registration statements on Form S-3 (File No. 333-251851 and File No. 333-248751, respectively) with the Securities and Exchange Commission (“SEC”), which were declared effective on January 8, 2021 and October 1, 2020, respectively (the “January 2021 Shelf Registration” and “October 2020 Shelf Registration”). Both shelf registrations contain a base prospectus which covers the offering, issuance and sale of such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities, which together shall have an aggregate initial offering price not to exceed $200.0 million. A prospectus is included in the October 2020 Shelf Registration covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (“Cantor”) and/or Controlled Equity Offering SM Sales Agreement with Ladenburg Thalmann & Co. Inc. (such agreements, the “Sales Agreements”). These Sales Agreements were cancelled in December 2020. As of December 31, 2020, approximately $437.0 million of the securities registered under the Company’s effective shelf registrations, which include the January 2021 Shelf Registration, October 2020 Shelf Registration, and the Form S-3 shelf registration filed by the Company in August 2018 (effective September 14, 2018), are available to be offered, issued and sold by the Company. Reverse Stock Split On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 On the effective date of July 17, 2020, the number of the Company’s issued and outstanding shares of common stock was decreased from 105,083,291 to 10,508,302 and the par value per common share remained unchanged. No fractional shares were issued as a result of the reverse stock split. presented in these consolidated financial statements have been retroactively adjusted for the reverse stock split and certain items in the prior period financial statements have been revised to conform to the current presentation. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account. Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively. See Note 8 for further details on the nature of the restricted cash. Short-Term Investments The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified. Warrant Liabilities The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. See Notes 9 and 12 for further details. Convertible Debt and Derivative Liabilities In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with FASB Accounting Standards Codification (“ Derivatives and Hedging Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. Amortization of Debt Issuance Costs and Discount The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee. The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt. Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020. The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method. The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations. Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods. Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC Earnings Per Share The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive: December 31, 2020 2019 Outstanding stock options 830,343 526,070 Outstanding restricted stock units 29,087 96,637 Warrants to purchase common stock associated with June 2016 Public Offering 421,867 421,867 Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering 4,472,205 4,472,205 Option to purchase common stock associated with December 2019 Public Offering — 583,333 Warrants to purchase common stock associated with December 2020 Public Offering - Series 1 6,800,000 — Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 — For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance for the conversion of the April 2020 Notes 1,299,790 — Warrants to purchase common stock associated with Solar loan agreement 12,243 12,243 Total 22,602,545 8,049,365 Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019. In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities. Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019. All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia. All sales, including sales outside of the United States, are denominated in United States dollars. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes , and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Short-term Investments

Short-term Investments	12 Months Ended
	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Short-term Investments	3. Short-term Investments The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands): Amortized Cost Unrealized Gains Unrealized Losses Fair Value As of December 31, 2019 U.S. government securities $ 1,996 $ 15 $ (14 ) $ 1,997 Commercial paper 998 — — 998 Overnight repurchase agreement 3,500 — — 3,500 Total short-term investments $ 6,494 $ 15 $ (14 ) $ 6,495 As of December 31, 2019, the Company had $6.5 million of held-to-maturity investments which all matured as of December 31, 2020. The gross unrealized gains and losses for the Company's commercial paper and overnight repurchase agreement are not significant

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2020 2019 Prepaid research and development services $ 1,535 $ 3,043 Prepaid insurance 362 252 Other prepaid expenses 19 19 Other receivable 2,876 — Other current assets 373 674 Total prepaid expenses and other current assets $ 5,165 $ 3,988

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment consisted of the following (in thousands): December 31, 2020 2019 Furniture and fixtures $ 406 $ 406 Computer equipment 76 73 Other 98 98 580 577 Less: accumulated depreciation and amortization (282 ) (172 ) Total property and equipment, net $ 298 $ 405

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued Expenses	6 . Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2020 2019 Accrued research and development expenses $ 991 $ 1,296 Accrued employee bonus compensation 2,190 1,798 Other accrued expenses 960 707 Total accrued expenses $ 4,141 $ 3,801

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Borrowings	7. Borrowings April 2020 Note Purchase Agreement On April 9, 2020, the Company entered into a Senior Convertible Note Purchase Agreement (the “April 2020 Note Purchase Agreement”) advisory fee and other issuance costs The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased. The April 2020 Notes constitute general, senior unsecured obligations of the Company. As of December 31, 2020, the Company’s April 2020 Notes consists of the convertible debt balance of $1.2 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.1 million, and the bifurcated embedded conversion option derivative liability of $3.3 million. In connection with the Company’s issuance of its April 2020 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging , at its initial fair value of $8.1 million as the interest make-whole provision is settled in shares of common stock. Debt issuance costs of $0.4 million initially allocated to the derivative liability were written off upon issuance of the April 2020 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2020. For the year ended December 31, 2020, the Company recognized a gain of $1.7 million on the fair value adjustment for the derivative liability and recognized $0.2 million in amortization of debt issuance costs and discount for the year ended December 31, 2020, related to the April 2020 Notes. In June 2020, Puissance converted $2.0 million of the April 2020 Notes for 316,461 shares of common stock. Upon conversion of the $2.0 million of the April 2020 Notes, the Company recognized a $0.8 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.0 million and the fair value of the consideration issued of $2.8 million. In December 2020 and January 2021, Puissance converted the remaining $2.0 million and $6.0 million of the April 2020 Notes for 322,348 and 959,080 shares of common stock, respectively. Upon conversion of the $2.0 million of the April 2020 Notes in December 2020, the Company recognized a $1.0 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $1.4 million and the fair value of the consideration issued of $2.4 million. The Company estimated the fair value of the convertible debt and derivative liability for the April 2020 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020, the fair value of the April 2020 Notes is $7.4 million. The holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock. The initial conversion rate is 111.1108 shares of common stock per $1,000 principal amount of the April 2020 Notes, which is equivalent to an initial conversion price of approximately $9.00 per share, and is subject to adjustment in certain events described in the April 2020 Note Purchase Agreement. Holders who convert may also be entitled to receive, under certain circumstances, an “interest make-whole payment” (as defined in the April 2020 Note Purchase Agreement) payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its April 2020 Notes in connection with such a corporate event. Unless the Company seeks and receives stockholder approval, the number of shares that the Company may deliver in connection with a conversion of the April 2020 Notes, including those delivered in connection with an “interest make-whole payment” or a “make-whole fundamental change” (each as defined in the April 2020 Note Purchase Agreement), will not exceed a cap of 1,938,600 shares of common stock On or after April 15, 2023, the Company has the right, at its election, to redeem all or any portion of the April 2020 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the April 2020 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If a “fundamental change” (as defined in the April 2020 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the April 2020 Notes for cash at a repurchase price of 100% of the principal amount of the April 2020 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. March 2019 Note Purchase Agreement On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its March 2019 Notes, resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs. The Company used the net proceeds to pay the remaining outstanding Solar term loan in full and recorded a loss on debt extinguishment of $0.8 million during the year ended December 31, 2019. The loss on debt extinguishment of $0.8 million for the year ended December 31, 2019 was recognized as the difference between the reacquisition price of the outstanding Solar debt of $15.9 million and the $15.1 million net carrying value of the Solar debt obligation prior to repayment. As of December 31, 2020 and 2019, the Company’s March 2019 Notes consists of the convertible debt balance of $9.4 million and $8.3 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.4 million and $0.5 million, and the bifurcated embedded conversion option derivative liability of $2.7 million and $3.2 million, respectively. In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging , at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock. Debt issuance costs of $0.6 million initially allocated to the derivative liability were written off upon issuance of the March 2019 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2019. For the years ended December 31, 2020 and 2019, the Company recognized gains of $0.5 million and $1.6 million, respectively, on the fair value adjustment for the derivative liability. For the years ended December 31, 2020 and 2019, the Company recognized $1.0 million and $1.1 million, respectively, in amortization of debt issuance costs and discount, related to the March 2019 Notes. In April 2019, Puissance converted $2.0 million of the March 2019 Notes for 162,600 shares of common stock. Upon conversion of the $2.0 million of the March 2019 Notes, the Company recognized a $0.2 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.8 million and the fair value of the consideration issued of $3.0 million The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020 and 2019, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.9 million and $11.7 million, respectively. The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the March 2019 Notes being issued to one financially sophisticated investor. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company. The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per $1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately $13.53 and is subject to adjustment in certain events described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per $1,000 principal amount of the March 2019 Notes. On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. Solar Loan Agreement On September 30, 2016, the Company entered into a loan agreement with Solar Capital Ltd. (“Solar”), in its capacity as administrative and collateral agent and as lender. Pursuant to the loan agreement, Solar was providing the Company with a 48-month secured term loan in the amount of $15.0 million. The term loan bore interest at a floating rate equal to the LIBOR rate in effect plus 8.49%. The Solar term loan was paid in full in March 2019

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8 . Commitments and Contingencies Leases On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year . The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance. The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability. The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease. Years Ended December 31, 2020 2019 Operating lease cost $ 664 $ 664 Variable lease cost 51 41 Total operating lease expense $ 715 $ 705 Cash paid for amounts included in the measurement of operating lease liability $ 507 $ 497 December 31, 2020 December 31, 2019 Remaining Lease term (years) 8.59 9.59 Discount rate 15 % 15 % Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands): December 31, 2020 2021 $ 517 2022 527 2023 715 2024 730 2025 744 Thereafter 2,789 Total $ 6,022 The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands): December 31, 2020 Present value of future minimum lease payments $ 3,326 Operating lease liability, current portion $ 52 Operating lease liability, long-term portion 3,274 Total operating lease liability $ 3,326 Difference between future minimum lease payments and discounted cash flows $ 2,696 Operating lease right-of-use asset $ 2,999 License Arrangements with Potential Future Expenditures As of December 31, 2020, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the “Deferred Milestone”). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. The milestone payment was recognized in the consolidated statement of operations in research and development expense for the year ended December 31, 2019 and is included in cash used in operating activities on the consolidated statement of cash flows. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of a NDA, triggered by the FDA acceptance for filing of its NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for the Company’s NDA for ibrexafungerp for the treatment of VVC. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged. Clinical Development Arrangements The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice. Other License Arrangements In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. For the years ended December 31, 2020 and 2019, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained. Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone and for the years ended December 31, 2020 and 2019, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	9 . Stockholders’ Equity Authorized, Issued, and Outstanding Common Shares The Company’s authorized common stock has a par value of $0.001 per share and consists of 100,000,000 shares as of December 31, 2020 and 2019; 19,663,698 and 9,741,372 shares were issued and outstanding at December 31, 2020, and December 31, 2019, respectively. On June 18, 2019, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 125,000,000 to 250,000,000. On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding. No fractional shares were issued as a result of the reverse stock split. Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: December 31, 2020 2019 Outstanding stock options 830,343 526,070 Outstanding restricted stock units 29,087 96,637 Warrants to purchase common stock associated with June 2016 Public Offering 421,867 421,867 Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering 4,472,205 4,472,205 Option to purchase common stock associated with December 2019 Public Offering — 583,333 Warrants to purchase common stock associated with December 2020 Public Offering - Series 1 6,800,000 — Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 — Prefunded warrants to purchase common stock associated with December 2020 Public Offering 5,260,000 — Warrants to purchase common stock associated with Solar loan agreement 12,243 12,243 For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance for the conversion of the April 2020 Notes 1,299,790 — For possible future issuance under 2014 Equity Incentive Plan (Note 11) 146,488 55,478 For possible future issuance under Employee Stock Purchase Plan (Note 11) 5,895 7,423 For possible future issuance under 2015 Inducement Award Plan (Note 11) 14,050 31,550 Total common shares reserved for future issuance 28,028,978 8,143,816 Liquidation Rights In the event of any liquidation or dissolution of the Company, the holders of the common stock are entitled to the remaining assets of the Company legally available for distribution. Dividends and Voting Rights The holders of the common stock are entitled to receive dividends if and when declared by the Company. Preferred Stock On May 7, 2014, the Company amended and restated its articles of incorporation relating to its approved capital structure. The Company’s board of directors has authorized the Company, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. The Company’s board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by the stockholders. The Company ’ s board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. There were no shares of preferred stock issued and outstanding as of December 31, 2020 and 2019 . December 2020 Public Offering On December 17, 2020, the Company completed a public offering (the “December 2020 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration. The Company sold an aggregate of (a) 8,340,000 shares of the Company’s common stock, par value $0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 5,260,000 shares of the Company’s common stock, par value $0.001 per share, and (c) two series of warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 13,600,000 shares of the Company’s common stock. The pre-funded warrants entitle the holders to purchase up to 5,260,000 shares of common stock and have an unlimited term and an exercise price of $0.001 per share. Each of the two series of warrants entitle the holders to purchase up to an aggregate of 6,800,000 shares of common stock. The prefunded warrants are classified as equity in accordance with ASC 815, Derivatives and Hedging The Series 1 warrants have a one-year three-and-a-half-year December 2019 Public Offering On December 12, 2019, 3,888,888 The warrants to purchase shares of common stock are immediately exercisable and expire on the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023, and have an exercise price of $11.0 per share. There is not expected to be any trading market for the warrants. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership. March 2018 Public Offering On March 8, 2018, 1,775,150 Each purchaser received a warrant to purchase 0.75 of a share of common stock (the “March 2018 Series 1 warrants”) and 0.45 of a share of common stock (the “March 2018 Series 2 warrants”) for each share purchased in the March 2018 Public Offering. The March 2018 Series 1 warrants to purchase in the aggregate up to 1,331,370 shares of common stock had a 53-week five-year beneficial ownership. During the year ended December 31, 2019, there were of the March 2018 Series 1 warrants exercised for total proceeds of $ 0.2 million and the March 2018 Series 1 warrants expired on March 14, 2019 . June 2016 Public Offering On June 21, 2016, the Company completed a public offering (the “June 2016 Public Offering”) and sold 937,500 shares of its common stock and warrants to purchase up to 421,867 shares of the Company’s common stock. Each purchaser received a warrant to purchase 0.45 of a share for each share purchased in the June 2016 Public Offering. There is not expected to be any trading market for the warrants. Each warrant was exercisable immediately upon issuance, will expire five years from the date of issuance, and has an exercise price of $30.0 per share. Warrant Liabilities The June 2016, March 2018, December 2019, and December 2020 warrants contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity ssuance costs of $1.9 million and $1.0 million initially allocated to the December 2020 Public Offering and December 2019 Public Offering warrant liabilities, respectively, were written off upon settlement and were recognized in the loss on the fair value adjustment for the warrant liabilities for the years ended December 31, 2020 and 2019, respectively. Common Stock Purchase Agreement On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to $20.0 million in shares of the Company’s common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement. The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company’s common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds $8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock. During the year ended December 31, 2020, the Company sold 125,000 shares of its common stock under the Common Stock Purchase Agreement for gross proceeds of $0.6 million. Under the Common Stock Purchase Agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 25,000 shares of Common Stock per business day, up to $20.0 million of common stock in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of: • the lowest sale price of Common Stock on the purchase date; or • the arithmetic average of the three (3) lowest closing sale prices for Common Stock during the ten (10) consecutive trading days ending on the trading day immediately preceding the purchase date. The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 200,000 shares per business day. In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount equal to at least 25,000 shares, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of Common Stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares the Company may determine. The purchase price per share pursuant to such VWAP Purchase Notice is generally the lessor of (i) the closing sale price on the VWAP Purchase Date, or (ii) 97% of the volume-weighted average price for common stock traded on its principal market on the VWAP Purchase Date. The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Common Stock Purchase Agreement, so long as the most recent purchase has been completed. The Common Stock Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Common Stock Purchase Agreement on any purchase date where the closing sale price of common stock is less than $0.25. There are no trading volume requirements or restrictions under the Common Stock Purchase Agreement, and the Company will control the timing and amount of sales of common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Common Stock Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Common Stock Purchase Agreement. In consideration for entering into the Common Stock Purchase Agreement, concurrently with the execution of the Common Stock Purchase Agreement, the Company issued to Aspire Capital 70,910 shares of common stock (the “Commitment Shares”). The fair value of the Commitment Shares of $0.6 million was recognized in other expense in the consolidated statements of operations for the year ended December 31, 2020. The Common Stock Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of common stock during any time prior to the termination of the Common Stock Purchase Agreement. Any proceeds that the Company receives under the Common Stock Purchase Agreement are expected to be used for general corporate purposes, including working capital. Warrant Associated with Solar Loan Agreement Pursuant to a loan agreement, the Company issued to Solar a warrant to purchase an aggregate of up to 12,243 shares of the Company’s common stock at an exercise price of $36.754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders’ equity section of the balance sheet.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	1 0 . Income Taxes The Company’s consolidated financial statements include a total tax benefit of $3.1 million and zero on loss before taxes of $58.3 million and $53.7 million for the years ended December 31, 2020 and 2019, respectively, and was generated entirely in the United States and Australia. Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands): 2020 2019 Amount Percent of Pretax Income Amount Percent of Pretax Income Income taxes from continuing operations at statutory rate $ (12,250 ) 21.0 % $ (11,279 ) 21.0 % State income taxes (4,108 ) 7.0 % (3,778 ) 7.0 % State effect of permanent items 78 (0.1 )% 285 (0.5 )% Stock-based compensation 96 (0.2 )% 100 (0.2 )% Deferred rate change — — (905 ) 1.6 % Warrants issuance 131 (0.2 )% 733 (1.4 )% Other 206 (0.3 )% 883 (1.5 )% NOL sale 301 (0.5 )% — — R&D credit adjustment 2 — (2,760 ) 5.1 % Increase in valuation allowance 12,396 (21.3 )% 16,721 (31.1 )% Total income tax benefit $ (3,148 ) 5.4 % $ — — % The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands): December 31, 2020 2019 Noncurrent deferred tax assets (liabilities) Accrued expenses $ 148 $ 107 Stock-based compensation 2,591 2,436 Lease liability 935 945 Other (823 ) (856 ) Net operating loss carryforwards 70,936 58,073 Research and development credits 5,291 5,984 Total deferred tax assets 79,078 66,689 Valuation allowances (79,078 ) (66,689 ) Net deferred tax assets $ — $ — As of December 31, 2020 and 2019, the Company had available federal net operating loss (“NOL”) carryforwards of approximately $294.4 million and $242.4 million, respectively, and state and net operating loss carryforwards of approximately $202.7 million and $178.2 million, respectively. Approximately $169.6 million of the federal NOLs can be carried forward to future tax years and expire at various times through 2037. The federal NOLs generated in December 31, 2020 and 2019 of approximately $52.0 million and $47.5 million, respectively, are carried forward indefinitely and do not expire. The Company’s state and net operating loss carryforwards began to expire in 2019. As of December 31, 2020, the Company had available federal research and development credit carryforwards of $5.3 million which begin to expire in 2022. The New Jersey Technology Business Tax Certificate Transfer (NOL) program, administered by the New Jersey Economic Development Authority, enables approved biotechnology companies to sell their unused net operating losses (“NOLs”) and research and development tax credits to unaffiliated, profitable corporate taxpayers in the State of New Jersey up to a maximum lifetime benefit of $20.0 million per business. As of December 31, 2020, the Company has received approximately $9.9 million under the program. In April 2020, the Company received a cash receipt of approximately $3.1 million, from the sale of its state NOLs and research and development credits and recognized an income tax benefit of $3.1 million On December 22, 2017, the “Tax Cuts and Jobs Act” was signed into law. The tax reform has the following effects on the Company: (1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017, (2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January 1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or 80% of a taxpayer’s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31, 2017. As of December 31, 2020 and 2019, the Company has concluded that it is more likely than not that the Company will not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved. In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards are limited. Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and state income tax authorities. The Company applies ASC 740-10-25-5, Income Taxes Accounting for Uncertainty in Income Taxes The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands): December 31, 2020 2019 Unrecognized tax benefit—January 1 $ 436 $ 436 Additions for tax positions of current period — — Additions for tax positions of prior periods — — Deferred rate change — — Unrecognized tax benefit—December 31 $ 436 $ 436 None of the unrecognized tax benefits would, if recognized, affect the effective tax rate because the Company has recorded a valuation allowance to fully offset federal and state deferred tax assets. The Company has no tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the coming year. The Company has $0 provided for interest and penalties associated with uncertain tax positions.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	11 . Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan (“2014 Plan”), which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan, as amended on June 18, 2014 and February 25, 2015, is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, but excluding the automatic increases discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 112,273 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. Pursuant to the terms of the 2014 Plan, on January 1, 2020 and 2019, the Company automatically added 389,650 and 191,887 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of December 31, 2020, there were 146,488 shares of common stock available for future issuance under the 2014 Plan. 2015 Inducement Plan On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan (“2015 Plan”). The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635I(4). The 2015 Plan had an initial share reserve covering 45,000 shares of common stock. On June 9, 2019, the Company’s board of directors amended the 2015 Plan, and the initial share reserve for the 2015 Plan was increased from 45,000 to 90,000 shares of common stock. As of December 31, 2020, there were 14,050 shares of common stock available for future issuance under the 2015 Plan. During the year ended December 31, 2019, there were 11,500 granted options of the Company’s common stock under the 2015 Plan. Option Valuation Method The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements and forfeitures are recorded as incurred. The Company has elected to use the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable rather than for use in estimating the fair value of stock options subject to vesting and transferability restrictions. Using the Black-Scholes option-pricing model, the weighted-average fair value of options granted during 2020 and 2019 was $4.83 and $7.50 per option, respectively. The aggregate fair value of options granted during 2020 and 2019 was $1.7 million and $1.3 million, respectively. The assumptions used to estimate fair value and the resulting grant date fair values are as follows: Employees Non-employee Directors Years Ended December 31, Years Ended December 31, 2020 2019 2020 2019 Weighted average expected volatility 64.67 % 66.47 % 66.55 % 65.36 % Weighted average risk-free interest rate 1.18 % 2.47 % 0.36 % 2.11 % Weighted average expected term (in years) 5.97 6.03 5.50 5.54 The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value ($000) Outstanding — December 31, 2019 526,070 $ 30.55 7.62 $ 60 Granted 349,437 $ 8.17 Exercised (166 ) $ 8.60 Forfeited/expired (44,998 ) $ 23.50 Outstanding — December 31, 2020 830,343 $ 21.52 7.71 $ 96 Exercisable — December 31, 2020 447,802 $ 31.47 6.74 $ 22 Vested or expected to vest —December 31, 2020 830,343 $ 21.52 7.71 $ 96 The intrinsic values in the table above represent the total intrinsic value (the difference between the Company’s closing stock price as of December 31, 2020, and the exercise price multiplied by the number of options). The total fair value of shares vested for both the years ended December 31, 2020 and 2019 was $1.3 million and $1.5 million, respectively. As of December 31, 2020, there was approximately $2.0 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted-average period of 2.4 years. Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2019 96,637 $ 14.18 Granted 28,695 $ 8.18 Vested (78,859 ) $ 14.05 Forfeited (17,386 ) $ 12.68 Non-vested at December 31, 2020 29,087 $ 9.52 The fair value of RSUs is based on the market price of the Company's common stock on the date of grant. RSUs generally vest 25% annually over a four year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period. As of December 31, 2020, there was approximately $0.2 million of total unrecognized compensation cost related to unvested RSU share-based compensation. That cost is expected to be recognized over a weighted-average period of 2.8 years. 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“2014 ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the 2014 ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the 2014 ESPP will not exceed 4,779 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 2,941 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The 2014 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. During the years ended December 31, 2020 and 2019, the Company issued 4,497 and 3,684 shares of common stock under the 2014 ESPP, respectively. During the years ended December 31, 2020 and 2019, the number of shares of common stock available for issuance under the ESPP was automatically increased by 2,941 shares. As of December 31, 2020, there were 5,895 shares of common stock available for future issuance under the 2014 ESPP. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the 2014 ESPP was $2.2 million and $1.8 million for the years ended December 31, 2020 and 2019, respectively. The total income tax benefit recognized in the consolidated statements of operations for share-based compensation arrangements was $0 for the years ended December 31, 2020 and 2019, respectively. Cash received from options exercised was $2,000 and $12,000 for the years ended December 31, 2020 and 2019, respectively. Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands): Years Ended December 31, 2020 2019 Research and development $ 806 $ 604 Selling, general and administrative 1,414 1,224 Total stock-based compensation expense $ 2,220 $ 1,828

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	12 . Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2020 Cash $ 117 $ 117 — — Restricted cash 273 273 — — Money market funds 92,924 92,924 — — Total assets $ 93,314 $ 93,314 — — Warrant liabilities $ 51,156 — — $ 51,156 Derivative liabilities 5,954 — — 5,954 Total liabilities $ 57,110 — — $ 57,110 December 31, 2019 Cash $ 23 $ 23 — — Restricted cash 273 273 — — Money market funds 41,897 41,897 — — Total assets $ 42,193 $ 42,193 — — Warrant liabilities $ 18,396 — — $ 18,396 Derivative liability 3,192 3,192 Total liabilities $ 21,588 — — $ 21,588 The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants. At December 31, 2020, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 71.8% to 86.6% and 78.0%, respectively. Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable input given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023. The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected terms. The weighted average expected term is 1.2 years as of December 31, 2020 for the December 2019 Public Offering warrants with a range of 0.9 to 2.5 years The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of December 31, 2020, these inputs were 58.1%, 1,458 basis points, and 14.9%, respectively. The range of volatilities were 56.5% to 60.1%. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The discount for lack of marketability, 7.0 % as of December 31, 2020 , is applied to the value of the March 2019 Notes. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Warrant Liabilities Balance – January 1, 2020 $ 18,396 December 2020 Public Offering 29,478 Loss adjustment to fair value 3,282 Balance – December 31, 2020 $ 51,156 Derivative Liabilities Balance – January 1, 2020 $ 3,192 Bifurcated embedded conversion option associated with April 2020 Notes 8,110 Adjustment for partial conversion of April 2020 Notes (2,690 ) Gain adjustment to fair value (2,658 ) Balance – December 31, 2020 $ 5,954

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	13 . Employee Benefit Plan The Company has a 401(k) retirement plan, which covers all U.S. employees scheduled for and working more than 20 hours per week. The Company may provide a discretionary match with a maximum amount of 50% of the first 6% of eligible participant’s compensation, which vests ratably over four years. Contributions under the plan were approximately $0.1 million for the years ended December 31, 2020 and 2019.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Pursuant to the terms of the 2014 Plan (see Note 11), on January 1, 2021, the Company automatically added 786,547 shares to the total number shares of common stock available for future issuance under the 2014 Plan. Pursuant to the terms of the 2014 ESPP (see Note 11), on January 1, 2021, the Company automatically added 2,941 shares to the total number shares of common stock available for future issuance under the 2014 ESPP. In January 2021, Puissance converted the remaining $6.0 million of the April 2020 Notes for 959,080 shares of common stock. In February 2021, the Company partnered with Amplity Inc. (“Amplity”) for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC. Under the terms of the 5-year agreement, the Company will utilize the Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services. The Company will maintain full ownership of ibrexafungerp and control of all strategic aspects of the launch. Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), which the Company will repay over three years starting in 2023. Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets. On February 11, 2021, the Company entered into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively. See Note 8 for further details on the nature of the restricted cash.
Short-Term Investments	Short-Term Investments The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified.
Warrant Liabilities	Warrant Liabilities The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. See Notes 9 and 12 for further details.
Convertible Debt and Derivative Liabilities	Convertible Debt and Derivative Liabilities In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with FASB Accounting Standards Codification (“ Derivatives and Hedging
Research and Development	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel.
Patent Expenses	Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Amortization of Debt Issuance Costs and Discount	Amortization of Debt Issuance Costs and Discount The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee. The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt. Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020. The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method. The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations.
Income Taxes	Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.
Stock-Based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.
Basic and Diluted Net Loss per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC Earnings Per Share The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive: December 31, 2020 2019 Outstanding stock options 830,343 526,070 Outstanding restricted stock units 29,087 96,637 Warrants to purchase common stock associated with June 2016 Public Offering 421,867 421,867 Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering 4,472,205 4,472,205 Option to purchase common stock associated with December 2019 Public Offering — 583,333 Warrants to purchase common stock associated with December 2020 Public Offering - Series 1 6,800,000 — Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 — For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance for the conversion of the April 2020 Notes 1,299,790 — Warrants to purchase common stock associated with Solar loan agreement 12,243 12,243 Total 22,602,545 8,049,365
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019. In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities. Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019. All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia. All sales, including sales outside of the United States, are denominated in United States dollars.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes , and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive: December 31, 2020 2019 Outstanding stock options 830,343 526,070 Outstanding restricted stock units 29,087 96,637 Warrants to purchase common stock associated with June 2016 Public Offering 421,867 421,867 Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering 4,472,205 4,472,205 Option to purchase common stock associated with December 2019 Public Offering — 583,333 Warrants to purchase common stock associated with December 2020 Public Offering - Series 1 6,800,000 — Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 — For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance for the conversion of the April 2020 Notes 1,299,790 — Warrants to purchase common stock associated with Solar loan agreement 12,243 12,243 Total 22,602,545 8,049,365

Short-term Investments (Tables)

Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Held-to-maturity Securities	The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands): Amortized Cost Unrealized Gains Unrealized Losses Fair Value As of December 31, 2019 U.S. government securities $ 1,996 $ 15 $ (14 ) $ 1,997 Commercial paper 998 — — 998 Overnight repurchase agreement 3,500 — — 3,500 Total short-term investments $ 6,494 $ 15 $ (14 ) $ 6,495

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2020 2019 Prepaid research and development services $ 1,535 $ 3,043 Prepaid insurance 362 252 Other prepaid expenses 19 19 Other receivable 2,876 — Other current assets 373 674 Total prepaid expenses and other current assets $ 5,165 $ 3,988

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): December 31, 2020 2019 Furniture and fixtures $ 406 $ 406 Computer equipment 76 73 Other 98 98 580 577 Less: accumulated depreciation and amortization (282 ) (172 ) Total property and equipment, net $ 298 $ 405

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): December 31, 2020 2019 Accrued research and development expenses $ 991 $ 1,296 Accrued employee bonus compensation 2,190 1,798 Other accrued expenses 960 707 Total accrued expenses $ 4,141 $ 3,801

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease	The following table summarizes certain quantitative information associated with the amounts recognized in the accompanying consolidated financial statements for the Lease (dollars in thousands): Years Ended December 31, 2020 2019 Operating lease cost $ 664 $ 664 Variable lease cost 51 41 Total operating lease expense $ 715 $ 705 Cash paid for amounts included in the measurement of operating lease liability $ 507 $ 497 December 31, 2020 December 31, 2019 Remaining Lease term (years) 8.59 9.59 Discount rate 15 % 15 %
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands): December 31, 2020 2021 $ 517 2022 527 2023 715 2024 730 2025 744 Thereafter 2,789 Total $ 6,022
Presentation of Operating Lease Liability and Right-of-Use Asset	The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands): December 31, 2020 Present value of future minimum lease payments $ 3,326 Operating lease liability, current portion $ 52 Operating lease liability, long-term portion 3,274 Total operating lease liability $ 3,326 Difference between future minimum lease payments and discounted cash flows $ 2,696 Operating lease right-of-use asset $ 2,999

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Common Stock Reserved For Future Issuances	The Company had reserved shares of common stock for future issuance as follows: December 31, 2020 2019 Outstanding stock options 830,343 526,070 Outstanding restricted stock units 29,087 96,637 Warrants to purchase common stock associated with June 2016 Public Offering 421,867 421,867 Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 798,810 798,810 Warrants to purchase common stock associated with December 2019 Public Offering 4,472,205 4,472,205 Option to purchase common stock associated with December 2019 Public Offering — 583,333 Warrants to purchase common stock associated with December 2020 Public Offering - Series 1 6,800,000 — Warrants to purchase common stock associated with December 2020 Public Offering - Series 2 6,800,000 — Prefunded warrants to purchase common stock associated with December 2020 Public Offering 5,260,000 — Warrants to purchase common stock associated with Solar loan agreement 12,243 12,243 For possible future issuance for the conversion of the March 2019 Notes 1,138,200 1,138,200 For possible future issuance for the conversion of the April 2020 Notes 1,299,790 — For possible future issuance under 2014 Equity Incentive Plan (Note 11) 146,488 55,478 For possible future issuance under Employee Stock Purchase Plan (Note 11) 5,895 7,423 For possible future issuance under 2015 Inducement Award Plan (Note 11) 14,050 31,550 Total common shares reserved for future issuance 28,028,978 8,143,816

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands): 2020 2019 Amount Percent of Pretax Income Amount Percent of Pretax Income Income taxes from continuing operations at statutory rate $ (12,250 ) 21.0 % $ (11,279 ) 21.0 % State income taxes (4,108 ) 7.0 % (3,778 ) 7.0 % State effect of permanent items 78 (0.1 )% 285 (0.5 )% Stock-based compensation 96 (0.2 )% 100 (0.2 )% Deferred rate change — — (905 ) 1.6 % Warrants issuance 131 (0.2 )% 733 (1.4 )% Other 206 (0.3 )% 883 (1.5 )% NOL sale 301 (0.5 )% — — R&D credit adjustment 2 — (2,760 ) 5.1 % Increase in valuation allowance 12,396 (21.3 )% 16,721 (31.1 )% Total income tax benefit $ (3,148 ) 5.4 % $ — — %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands): December 31, 2020 2019 Noncurrent deferred tax assets (liabilities) Accrued expenses $ 148 $ 107 Stock-based compensation 2,591 2,436 Lease liability 935 945 Other (823 ) (856 ) Net operating loss carryforwards 70,936 58,073 Research and development credits 5,291 5,984 Total deferred tax assets 79,078 66,689 Valuation allowances (79,078 ) (66,689 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands): December 31, 2020 2019 Unrecognized tax benefit—January 1 $ 436 $ 436 Additions for tax positions of current period — — Additions for tax positions of prior periods — — Deferred rate change — — Unrecognized tax benefit—December 31 $ 436 $ 436

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Assumptions Used To Estimate Fair Value of Options	The assumptions used to estimate fair value and the resulting grant date fair values are as follows: Employees Non-employee Directors Years Ended December 31, Years Ended December 31, 2020 2019 2020 2019 Weighted average expected volatility 64.67 % 66.47 % 66.55 % 65.36 % Weighted average risk-free interest rate 1.18 % 2.47 % 0.36 % 2.11 % Weighted average expected term (in years) 5.97 6.03 5.50 5.54
Schedule of Share-based Compensation, Stock Options, Activity	The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value ($000) Outstanding — December 31, 2019 526,070 $ 30.55 7.62 $ 60 Granted 349,437 $ 8.17 Exercised (166 ) $ 8.60 Forfeited/expired (44,998 ) $ 23.50 Outstanding — December 31, 2020 830,343 $ 21.52 7.71 $ 96 Exercisable — December 31, 2020 447,802 $ 31.47 6.74 $ 22 Vested or expected to vest —December 31, 2020 830,343 $ 21.52 7.71 $ 96
Schedule of Restricted Stock Units ("RSU") Activity	Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2019 96,637 $ 14.18 Granted 28,695 $ 8.18 Vested (78,859 ) $ 14.05 Forfeited (17,386 ) $ 12.68 Non-vested at December 31, 2020 29,087 $ 9.52
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands): Years Ended December 31, 2020 2019 Research and development $ 806 $ 604 Selling, general and administrative 1,414 1,224 Total stock-based compensation expense $ 2,220 $ 1,828

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured on a Recurring Basis	The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2020 Cash $ 117 $ 117 — — Restricted cash 273 273 — — Money market funds 92,924 92,924 — — Total assets $ 93,314 $ 93,314 — — Warrant liabilities $ 51,156 — — $ 51,156 Derivative liabilities 5,954 — — 5,954 Total liabilities $ 57,110 — — $ 57,110 December 31, 2019 Cash $ 23 $ 23 — — Restricted cash 273 273 — — Money market funds 41,897 41,897 — — Total assets $ 42,193 $ 42,193 — — Warrant liabilities $ 18,396 — — $ 18,396 Derivative liability 3,192 3,192 Total liabilities $ 21,588 — — $ 21,588
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Warrant Liabilities Balance – January 1, 2020 $ 18,396 December 2020 Public Offering 29,478 Loss adjustment to fair value 3,282 Balance – December 31, 2020 $ 51,156 Derivative Liabilities Balance – January 1, 2020 $ 3,192 Bifurcated embedded conversion option associated with April 2020 Notes 8,110 Adjustment for partial conversion of April 2020 Notes (2,690 ) Gain adjustment to fair value (2,658 ) Balance – December 31, 2020 $ 5,954

Description of Business and B_2

Description of Business and Basis of Preparation - Additional Information (Detail)	Jan. 08, 2021USD ($)	Oct. 01, 2020USD ($)	Jul. 17, 2020shares	Jul. 16, 2020shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Jun. 18, 2019shares	Jun. 17, 2019shares	Dec. 31, 2018shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit					$ (326,613,000)	$ (271,428,000)
Cash and cash equivalents					93,041,000	$ 41,920,000
Shelf registration maximum equity offering price					$ 437,000,000
Reverse stock split, ratio				0.1
Common stock, shares authorized (in shares) | shares			100,000,000	250,000,000	100,000,000	100,000,000	250,000,000	125,000,000
Common stock, shares issued (in shares) | shares			10,508,302	105,083,291	19,663,698	9,741,372
Common stock, shares outstanding (in shares) | shares			10,508,302	105,083,291	19,663,698	9,741,372
Stock issued during period as result of reverse stock splits | shares			0	0
Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, shares outstanding (in shares) | shares					19,663,698	9,741,372			4,797,198
October 2020 Shelf Registration
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity initial offering price		$ 200,000,000
October 2020 Shelf Registration | Sales Agreement | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity offering price		$ 50,000,000
Subsequent Event | January 2021 Shelf Registration
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity initial offering price	$ 200,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Subsidiary, Sale of Stock [Line Items]
Cash, cash equivalents, and restricted cash | $	$ 93,314	$ 42,193	$ 11,767
Operating segments (number) | Segment	1
ASU 2018-13
Subsidiary, Sale of Stock [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Dec. 31, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Accounting Standards Update [Extensible List]	ASU 2018-13
6.0% April 2020 and March 2019 Convertible Senior Notes
Subsidiary, Sale of Stock [Line Items]
Interest rate	6.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	22,602,545	8,049,365
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	830,343	526,070
Outstanding restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	29,087	96,637
For possible future issuance for the conversion of the March 2019 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,138,200	1,138,200
For possible future issuance for the conversion of the April 2020 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,299,790	0
Warrants to purchase common stock associated with Solar loan agreement | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	12,243	12,243
Warrants to purchase common stock associated with June 2016 Public Offering | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	421,867	421,867
March 2018 Public Offering Series 2 [Member] | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	798,810	798,810
December 2020 Public Offering Series 1 | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	6,800,000	0
December 2020 Public Offering Series 2 | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	6,800,000	0
December 2019 Public Offering | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	4,472,205	4,472,205
December 2019 Public Offering | Option to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	583,333

Short-term Investments (Details

Short-term Investments (Details) $ in Thousands	Dec. 31, 2019USD ($)
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$ 6,494
Unrealized Gains	15
Unrealized Losses	(14)
Fair Value	6,495
Commercial paper
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	998
Unrealized Gains	0
Unrealized Losses	0
Fair Value	998
Overnight repurchase agreement
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	3,500
Unrealized Gains	0
Unrealized Losses	0
Fair Value	3,500
U.S. government securities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	1,996
Unrealized Gains	15
Unrealized Losses	(14)
Fair Value	$ 1,997

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) $ in Millions	Dec. 31, 2019USD ($)
Investments Debt And Equity Securities [Abstract]
Held-to-maturity investments	$ 6.5

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid research and development services	$ 1,535	$ 3,043
Prepaid insurance	362	252
Other prepaid expenses	19	19
Other receivable	2,876	0
Other current assets	373	674
Total prepaid expenses and other current assets	$ 5,165	$ 3,988

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 580	$ 577
Less: accumulated depreciation and amortization	(282)	(172)
Total property and equipment, net	298	405
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	406	406
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	76	73
Other
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 98	$ 98

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 991	$ 1,296
Accrued employee bonus compensation	2,190	1,798
Other accrued expenses	960	707
Total accrued expenses	$ 4,141	$ 3,801

Borrowings - Additional Informa

Borrowings - Additional Information (Details)	Mar. 07, 2019USD ($)d$ / shares	Sep. 30, 2016USD ($)	Jan. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	Apr. 09, 2020USD ($)d$ / shares	Apr. 30, 2019USD ($)shares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Payment of debt issuance costs								$ 494,000	$ 1,253,000
Amortization of debt issuance costs and discount								1,201,000	1,171,000
Loss on extinguishment of debt								1,766,000	1,045,000
Net carrying amount of convertible debt and derivative liability				$ 16,516,000				$ 16,516,000	11,522,000
April 2020 Note Purchase Agreement
Debt Instrument [Line Items]
Date of issuance and sale of notes						Apr. 9, 2020
Face amount						$ 10,000,000
Proceeds from debt, net of issuance costs						9,500,000
Payment of debt issuance costs						$ 500,000
Purchase price as percentage of principal amount						100.00%
Interest rate						6.00%
Payment terms								The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased.
Notes maturity date						Apr. 15, 2026
Notes maturity description								The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased
Senior convertible notes				1,200,000				$ 1,200,000
Unamortized debt issuance cost				100,000				100,000
Bifurcated embedded conversion option derivative liability				3,300,000				3,300,000
Derivative, fair value				8,100,000				8,100,000
Debt issuance costs				400,000				400,000
Gain (loss) on fair value adjustment of derivative liability								1,700,000
Amortization of debt issuance costs and discount								200,000
Conversion of convertible note, amount				$ 2,000,000	$ 2,000,000
Conversion of convertible note exchanged for shares | shares				322,348	316,461
Loss on extinguishment of debt				$ 1,000,000	$ 800,000
Net carrying amount of convertible debt and derivative liability				1,400,000	2,000,000			1,400,000
Fair value of the consideration issued				2,400,000	$ 2,800,000			2,400,000
Fair value of convertible debt and derivative liability				7,400,000				$ 7,400,000
Conversion terms								holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock.
Conversion rate, number of shares to be issued per $1000 of principal (in shares)						111.1108
Principal amount of notes used as the denominator for conversion into notes						$ 1,000
Initial conversion price of notes | $ / shares						$ 9
Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events						1,938,600
Convertible notes, redemption start date						Apr. 15, 2023
Convertible notes, threshold percentage of stock price trigger						130.00%
Convertible notes, threshold trading days | d						20
Convertible notes, threshold consecutive trading days | d						30
Redemption price as percentage of the principal amount						100.00%
Redemption price as percentage of the principal amount subject to certain exceptions						100.00%
April 2020 Note Purchase Agreement | Subsequent Event
Debt Instrument [Line Items]
Conversion of convertible note, amount			$ 6,000,000
Conversion of convertible note exchanged for shares | shares			959,080
Senior Convertible Note Purchase Agreement
Debt Instrument [Line Items]
Date of issuance and sale of notes	Mar. 7, 2019
Face amount	$ 16,000,000
Proceeds from debt, net of issuance costs	14,700,000
Payment of debt issuance costs	$ 1,300,000
Purchase price as percentage of principal amount	100.00%
Interest rate	6.00%
Payment terms								The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.
Notes maturity date	Mar. 15, 2025
Notes maturity description								The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased
Senior convertible notes				9,400,000				$ 9,400,000	8,300,000
Unamortized debt issuance cost				400,000				400,000	500,000
Bifurcated embedded conversion option derivative liability				2,700,000				2,700,000	3,200,000
Derivative, fair value				7,000,000				7,000,000
Debt issuance costs				600,000				600,000
Gain (loss) on fair value adjustment of derivative liability								500,000	1,600,000
Amortization of debt issuance costs and discount								1,000,000	1,100,000
Conversion of convertible note, amount							$ 2,000,000
Conversion of convertible note exchanged for shares | shares							162,600
Loss on extinguishment of debt							$ 200,000		800,000
Net carrying amount of convertible debt and derivative liability							2,800,000
Fair value of the consideration issued							$ 3,000,000
Fair value of convertible debt and derivative liability				$ 12,900,000				$ 12,900,000	11,700,000
Conversion terms								holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock.
Conversion rate, number of shares to be issued per $1000 of principal (in shares)	73.9096
Principal amount of notes used as the denominator for conversion into notes	$ 1,000
Initial conversion price of notes | $ / shares	$ 13.53
Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events	81
Convertible notes, redemption start date	Mar. 15, 2022
Convertible notes, threshold percentage of stock price trigger	130.00%
Convertible notes, threshold trading days | d	20
Convertible notes, threshold consecutive trading days | d	30
Redemption price as percentage of the principal amount	100.00%
Redemption price as percentage of the principal amount subject to certain exceptions	100.00%
Reacquisition price of outstanding debt									15,900,000
Carrying value of debt obligation									$ 15,100,000
Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events	$ 1,000
Term Loan | Secured Debt
Debt Instrument [Line Items]
Face amount		$ 15,000,000
Loan agreement term		48 months
Term Loan | Secured Debt | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		8.49%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 01, 2018USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Commitment And Contingencies [Line Items]
Long-term lease agreement, area of office space | ft²	19,275
Lease term	11 years
Total lease payments	$ 7,300,000	$ 507,000	$ 497,000
Lessee, operating lease, existence of option to extend	true
Renewal term	5 years
Renewal term, description	The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease
Security deposit in the form of a standby letter of credit	$ 300,000
Decrease in security deposit	$ 55,000
Cypralis Limited | Asset Purchase Agreement
Commitment And Contingencies [Line Items]
Revenue recognized		0	0
Waterstone Pharmaceutical HK Limited | License Agreement
Commitment And Contingencies [Line Items]
Revenue recognized		0	$ 0
Maximum
Commitment And Contingencies [Line Items]
Milestone payments from the Company		$ 19,000,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail) - USD ($) $ in Thousands	Mar. 01, 2018	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Operating lease cost		$ 664	$ 664
Variable lease cost		51	41
Total operating lease expense		715	705
Total lease payments	$ 7,300	$ 507	$ 497
Remaining Lease term (years)		8 years 7 months 2 days	9 years 7 months 2 days
Discount rate		15.00%	15.00%

Commitments and Contingencies_3

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021	$ 517
2022	527
2023	715
2024	730
2025	744
Thereafter	2,789
Total	$ 6,022

Commitments and Contingencies_4

Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Present value of future minimum lease payments	$ 3,326
Operating lease liability, current portion	52	$ 36
Operating lease liability, long-term portion	3,274	3,326
Total operating lease liability	3,326
Difference between future minimum lease payments and discounted cash flows	2,696
Operating lease right-of-use asset	$ 2,999	$ 3,191

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands

Dec. 17, 2020USD ($)$ / sharesshares

Jul. 17, 2020shares

Jul. 16, 2020shares

Apr. 10, 2020USD ($)d$ / sharesshares

Dec. 12, 2019USD ($)$ / sharesshares

Mar. 08, 2018$ / sharesshares

Sep. 30, 2016$ / sharesshares

Jun. 21, 2016$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)shares

Jun. 18, 2019shares

Jun. 17, 2019shares

May 07, 2014$ / sharesshares

Schedule Of Capitalization Equity [Line Items]

Common stock, par value (in dollars per share) | $ / shares

$ 0.001

$ 0.001

Common stock, shares authorized (in shares)

100,000,000

250,000,000

100,000,000

100,000,000

250,000,000

125,000,000

Common stock, shares issued (in shares)

10,508,302

105,083,291

19,663,698

9,741,372

Common stock, shares outstanding (in shares)

10,508,302

105,083,291

19,663,698

9,741,372

Common stock, reverse stock split

1-for-10

Reverse stock split, ratio

0.1

Stock issued during period as result of reverse stock splits

0

0

Preferred stock, shares authorized (in shares)

5,000,000

5,000,000

5,000,000

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.001

$ 0.001

$ 0.001

Preferred stock, shares issued (in shares)

0

0

Preferred stock, shares outstanding (in shares)

0

0

Common stock issued, net of expenses (in shares)

1,775,150

937,500

Proceeds from common stock issued | $

$ 90,554

$ 46,337

Common stock issued, net of expenses | $

57,184

30,530

Warrant liabilities fair value adjustment | $

5,214

$ 4,497

Warrant liabilities | $

$ 51,200

Warrants to purchase common stock associated with Loan Agreement

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

12,243

Exercise price of warrants (in dollars per share) | $ / shares

$ 36.754

Warrant expiration period

5 years

Aspire Capital | Common Stock Purchase Agreement

Schedule Of Capitalization Equity [Line Items]

Common stock issued, net of expenses (in shares)

125,000

Proceeds from common stock issued | $

$ 600

Number of purchase aggregate shares of common stock

1,956,547

Percentage of common stock outstanding

19.99%

Number of shares committed

70,910

Average purchase price of shares sold | $ / shares

$ 8.461

Percentage of common stock owned

19.99%

Sale of common stock maximum number of share sold per business day

25,000

Stock purchase price average number of trading days lowest closing sales price out of consecutive trading days | d

3

Stock purchase price number of consecutive trading days | d

10

Increase in sale of common stock maximum number of share sold per business day

200,000

Percentage of purchase price per share

97.00%

Option to Purchase Common Stock

Schedule Of Capitalization Equity [Line Items]

Options expiration date

2020-01

Maximum | Aspire Capital | Common Stock Purchase Agreement

Schedule Of Capitalization Equity [Line Items]

Public offering price | $ / shares

$ 0.25

Sale of common stock at sole discretion | $

$ 20,000

Stock purchase percentage on aggregate shares of common stock traded

30.00%

Maximum | Option to Purchase Common Stock

Schedule Of Capitalization Equity [Line Items]

Number of options not exercised

583,333

Series 1 Warrant

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

11,550

Warrants, expiration date

Mar. 14, 2019

Proceeds from Warrant Exercises | $

$ 200

Common Stock

Schedule Of Capitalization Equity [Line Items]

Common stock, shares outstanding (in shares)

19,663,698

9,741,372

4,797,198

Common stock issued, net of expenses (in shares)

9,156,304

4,773,692

Common stock issued, net of expenses | $

$ 9

$ 5

Commitment Shares | Aspire Capital | Common Stock Purchase Agreement

Schedule Of Capitalization Equity [Line Items]

Common stock shares issued

70,910

Commitment Shares | Aspire Capital | Common Stock Purchase Agreement | Other Expense

Schedule Of Capitalization Equity [Line Items]

Fair value of shares | $

600

December 2020 Public Offering

Schedule Of Capitalization Equity [Line Items]

Common stock, par value (in dollars per share) | $ / shares

$ 0.001

Common stock issued, net of expenses (in shares)

8,340,000

Exercise price of warrants (in dollars per share) | $ / shares

$ 0.001

Number of shares received per warrant (in shares)

6,800,000

Proceeds from common stock issued | $

$ 79,500

Warrant liabilities fair value adjustment | $

1,900

December 2020 Public Offering | Pre-funded Warrants

Schedule Of Capitalization Equity [Line Items]

Common stock, par value (in dollars per share) | $ / shares

$ 0.001

Number of warrants issued to purchase common stock (in shares)

5,260,000

Public offering price | $ / shares

$ 6.249

December 2020 Public Offering | Series 1 Warrant

Schedule Of Capitalization Equity [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 7.33

Warrant term

1 year

December 2020 Public Offering | Series 1 Warrant | Maximum

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

13,600,000

December 2020 Public Offering | Series 2 Warrant

Schedule Of Capitalization Equity [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 8.25

Warrant term

3 years 6 months

December 2020 Public Offering | Series 2 Warrant | Minimum

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

5,260,000

December 2020 Public Offering | Common Stock

Schedule Of Capitalization Equity [Line Items]

Public offering price | $ / shares

$ 6.25

December 2019 Public Offering

Schedule Of Capitalization Equity [Line Items]

Common stock issued, net of expenses (in shares)

3,888,888

Number of warrants issued to purchase common stock (in shares)

3,888,888

Exercise price of warrants (in dollars per share) | $ / shares

$ 11

Share price (in dollars per share) | $ / shares

$ 9

Common stock issued, net of expenses | $

$ 32,500

Warrants, expiration date

Jun. 12, 2023

Warrant liabilities fair value adjustment | $

$ 1,000

Underwriters | Maximum

Schedule Of Capitalization Equity [Line Items]

Option to purchase shares of common stock

583,333

Underwriters | Warrant liability

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

583,333

Number of warrants exercised

583,333

March 2018 Public Offering

Schedule Of Capitalization Equity [Line Items]

Public offering price | $ / shares

$ 16.90

March 2018 Public Offering | Series 1 Warrant

Schedule Of Capitalization Equity [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 18.5

Number of shares received per warrant (in shares)

0.75

Warrant term

371 days

March 2018 Public Offering | Series 1 Warrant | Maximum

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

1,331,370

March 2018 Public Offering | Series 2 Warrant

Schedule Of Capitalization Equity [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 20

Number of shares received per warrant (in shares)

0.45

Warrant term

5 years

March 2018 Public Offering | Series 2 Warrant | Maximum

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

798,810

March 2018 Public Offering | Warrant liability | Maximum

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

2,130,180

June 2016 Public Offering

Schedule Of Capitalization Equity [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 30

Number of shares received per warrant (in shares)

0.45

Warrant expiration period

5 years

June 2016 Public Offering | Warrant liability | Maximum

Schedule Of Capitalization Equity [Line Items]

Number of warrants issued to purchase common stock (in shares)

421,867

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Common shares reserved for future issuance	28,028,978	8,143,816
Stock options
Class of Stock [Line Items]
Common shares reserved for future issuance	830,343	526,070
Restricted Stock Units
Class of Stock [Line Items]
Common shares reserved for future issuance	29,087	96,637
December 2020 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	5,260,000	0
Warrant liability | June 2016 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	421,867	421,867
Warrant liability | December 2020 Public Offering Series 1
Class of Stock [Line Items]
Common shares reserved for future issuance	6,800,000	0
Warrant liability | December 2019 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	4,472,205	4,472,205
Warrant liability | Warrants to purchase common stock associated with Solar loan agreement
Class of Stock [Line Items]
Common shares reserved for future issuance	12,243	12,243
Warrant liability | December 2020 Public Offering Series 2
Class of Stock [Line Items]
Common shares reserved for future issuance	6,800,000	0
Series 2 Warrant | March 2018 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	798,810	798,810
Option to Purchase Common Stock | December 2019 Public Offering
Class of Stock [Line Items]
Common shares reserved for future issuance	0	583,333
March 2019 Notes
Class of Stock [Line Items]
Common shares reserved for future issuance	1,138,200	1,138,200
April 2020 Notes
Class of Stock [Line Items]
Common shares reserved for future issuance	1,299,790	0
2014 Equity Incentive Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	146,488	55,478
2014 Employee Stock Purchase Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	5,895	7,423
2015 Inducement Award Plan
Class of Stock [Line Items]
Common shares reserved for future issuance	14,050	31,550

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Income tax benefit		$ 3,148,000	$ 0
Loss before taxes		$ 58,333,000	$ 53,710,000
Corporate income tax rate		21.00%	21.00%
Temporary expensing for certain business assets and property, percent		100.00%
Maximum deduction percentage of pre-NOL taxable income		80.00%
Unrecognized tax benefits that would impact effective tax rate		$ 0
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit		0
Income tax examination, penalties and interest accrued		$ 0
Maximum
Operating Loss Carryforwards [Line Items]
Corporate income tax rate		21.00%		35.00%
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward		$ 294,400,000	$ 242,400,000
Tax credit carryforward		5,300,000
NOLs subject to expiration		169,600,000
NOLs subject not to expiration		$ 52,000,000	47,500,000
NOLs expiration date		Dec. 31, 2037
Net operating loss carryforwards expiration year		2022
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward		$ 202,700,000	$ 178,200,000
Net operating loss carryforwards expiration year		2019
State | New Jersey
Operating Loss Carryforwards [Line Items]
Cash receipt from the sale of state NOLs	$ 3,100,000
Maximum selling value of unused net operating losses and research and development tax credit to profitable tax payers.		$ 20,000,000
Amount received from the program		$ 9,900,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Amount
Income taxes from continuing operations at statutory rate	$ (12,250)	$ (11,279)
State income taxes	(4,108)	(3,778)
State effect of permanent items	78	285
Stock-based compensation	96	100
Deferred rate change		(905)
Warrants issuance	131	733
Other	206	883
NOL sale	301
R&D credit adjustment	2	(2,760)
Increase in valuation allowance	12,396	16,721
Total income tax benefit	$ (3,148)	$ 0
Percent of Pretax Income
Income taxes from continuing operations at statutory rate	21.00%	21.00%
State income taxes	7.00%	7.00%
State effect of permanent items	(0.10%)	(0.50%)
Stock-based compensation	(0.20%)	(0.20%)
Deferred rate change	0.00%	1.60%
Warrants issuance	(0.20%)	(1.40%)
Other	(0.30%)	(1.50%)
NOL sale	(0.50%)	0.00%
R&D credit adjustment	0.00%	5.10%
Increase in valuation allowance	(21.30%)	(31.10%)
Total income tax benefit	5.40%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Accrued expenses	$ 148	$ 107
Stock-based compensation	2,591	2,436
Lease liability	935	945
Other	(823)	(856)
Net operating loss carryforwards	70,936	58,073
Research and development credits	5,291	5,984
Total deferred tax assets	79,078	66,689
Valuation allowances	(79,078)	(66,689)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits	$ 436	$ 436
Additions for tax positions of current period	0	0
Additions for tax positions of prior periods	0	0
Deferred rate change	0	0
Unrecognized tax benefits	$ 436	$ 436

Stock-based Compensation - 2009

Stock-based Compensation - 2009 Stock Option Plan (Details) - 2009 Stock Option Plan	12 Months Ended
	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period of options	10 years
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of exercise price	100.00%
Vesting period of options	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of exercise price	110.00%
Vesting period of options	4 years

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Details) - 2014 Equity Incentive Plan - shares	May 02, 2014	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional awards expected to be granted (in shares)	0
Expiration period of options		10 years
Common stock outstanding percentage	4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)	0
Share-based compensation arrangement by share-based payment award, number of additional shares authorized		389,650	191,887
Possible future issuance under equity compensation plan (in shares)		146,488
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of options		3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of options		4 years
Base number of new shares available for future issuance under equity incentive plan (in shares)	112,273
Common stock issuable period	10 years

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Plan (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jun. 09, 2019	Jun. 08, 2019	Mar. 26, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (shares)	349,437
2015 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized under the plan (in shares)			90,000	45,000	45,000
Granted (shares)	17,500	11,500
Possible future issuance under equity compensation plan (in shares)	14,050	31,550

Stock-based Compensation - Opti

Stock-based Compensation - Option Valuation Method - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average value of options granted in period (in dollars per share)	$ 4.83	$ 7.50
Aggregate fair value of options granted	$ 1.7	$ 1.3

Stock-based Compensation - Op_2

Stock-based Compensation - Option Valuation Method (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average expected volatility, employees	64.67%	66.47%
Weighted average expected volatility, non-employees directors	66.55%	65.36%
Weighted average risk-free interest rate, employees	1.18%	2.47%
Weighted average risk-free interest rate, non-employees directors	0.36%	2.11%
Weighted average expected term (in years), employees	5 years 11 months 19 days	6 years 10 days
Weighted average expected term (in years), non-employees directors	5 years 6 months	5 years 6 months 14 days

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Beginning balance - Outstanding (shares)	526,070
Granted (shares)	349,437
Exercised (shares)	(166)
Forfeited/expired (shares)	(44,998)
Ending balance - Outstanding (shares)	830,343	526,070
Exercisable (shares)	447,802
Vested or expected to vest (shares)	830,343
Weighted- Average Exercise Price
Beginning balance - Outstanding (in dollars per share)	$ 30.55
Granted (in dollars per share)	8.17
Exercised (in dollars per share)	8.60
Forfeited/expired (in dollars per share)	23.50
Ending balance - Outstanding (in dollars per share)	21.52	$ 30.55
Exercisable (in dollars per share)	31.47
Vested or expected to vest (in dollars per share)	$ 21.52
Weighted- Average Remaining Contractual Life (in years)
Balance - Outstanding	7 years 8 months 15 days	7 years 7 months 13 days
Exercisable	6 years 8 months 26 days
Vested or expected to vest	7 years 8 months 15 days
Aggregate Intrinsic Value ($000)
Balance - Outstanding	$ 96	$ 60
Exercisable	22
Vested and expected to vest	$ 96

Stock-based Compensation - St_2

Stock-based Compensation - Stock Option Activity - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Total fair value of shares vested during the year	$ 1.3	$ 1.5
Total unrecognized compensation cost related to unvested share-based compensation arrangements	$ 2
Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period	2 years 4 months 24 days

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Weighted Average Grant Date Fair Value Per Share
Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period	2 years 4 months 24 days
Restricted Stock Units
Number of Shares
Beginning balance - Outstanding (shares) | shares	96,637
Options granted in period (shares) | shares	28,695
Vested (shares) | shares	(78,859)
Forfeited (shares) | shares	(17,386)
Ending balance - Outstanding (shares) | shares	29,087
Weighted Average Grant Date Fair Value Per Share
Beginning balance - Outstanding (in dollars per share) | $ / shares	$ 14.18
Granted (in dollars per share) | $ / shares	8.18
Vested (in dollars per share) | $ / shares	14.05
Forfeited (in dollars per share) | $ / shares	12.68
Ending balance - Outstanding (in dollars per share) | $ / shares	$ 9.52
Vesting percentage	25.00%
Vesting period of options	4 years
Total unrecognized compensation cost related to unvested RSU share-based compensation | $	$ 0.2
Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period	2 years 9 months 18 days

Stock-based Compensation - 20_2

Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - 2014 Employee Stock Purchase Plan - shares	May 02, 2014	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan (in shares)	4,779
Common stock issuable period	10 years
Common stock outstanding percentage	0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding (in shares)	2,941
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)	0
Common stock issued through employee stock purchase plan (in shares)		4,497	3,684
Share-based compensation arrangement by share-based payment award, number of additional shares authorized		2,941	2,941
Possible future issuance under equity compensation plan (in shares)		5,895

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based compensation expense	$ 2,220,000	$ 1,828,000
Tax benefit from compensation expense	0	0
Cash received from option exercised	$ 2,000	$ 12,000

Stock-based Compensation - Expe

Stock-based Compensation - Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 2,220	$ 1,828
Research and development, net
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to stock options	806	604
Selling, general and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 1,414	$ 1,224

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 93,314	$ 42,193
Fair value of financial liabilities	57,110	21,588
Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	51,156	18,396
Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	5,954	3,192
Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	117	23
Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	273	273
Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	92,924	41,897
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	93,314	42,193
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	117	23
Quoted Prices in Active Markets for Identical Assets (Level 1) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	273	273
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	92,924	41,897
Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2) | Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Fair value of financial liabilities	57,110	21,588
Significant Unobservable Inputs (Level 3) | Warrant liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	51,156	18,396
Significant Unobservable Inputs (Level 3) | Derivative liabilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	5,954	3,192
Significant Unobservable Inputs (Level 3) | Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3) | Restricted cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3) | Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Significant Unobservable Inputs (Level 3)	Dec. 31, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, maturity date	Jun. 12, 2023
Stock Price Volatility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	58.1
Stock Price Volatility | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	71.8
Derivative liabilities, unobservable inputs rate	56.5
Stock Price Volatility | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	86.6
Derivative liabilities, unobservable inputs rate	60.1
Stock Price Volatility | Weighted Average
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, stock price volatility rate	78
Weighted Average Expected Term
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, expected term	1 year 2 months 12 days
Weighted Average Expected Term | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, expected term		10 months 24 days
Weighted Average Expected Term | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrant liabilities, expected term		2 years 6 months
Market Credit Spread
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	1,458
Estimated Yield
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative liabilities, unobservable inputs rate	14.9
Discounts for Lack of Marketability | March 2019 Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior convertible notes, unobservable inputs rate	7

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Warrant liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 18,396
December 2020 Public Offering	29,478
Gain (loss) adjustment to fair value	3,282
Ending balance	51,156
Derivative liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	3,192
Bifurcated embedded conversion option associated with Notes	8,110
Adjustment for partial conversion of April 2020 Notes	(2,690)
Gain (loss) adjustment to fair value	(2,658)
Ending balance	$ 5,954

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)hour	Dec. 31, 2019USD ($)
Compensation And Retirement Disclosure [Abstract]
Work hours per week | hour	20
Employer matching percent	50.00%
Maximum percentage of contributions per employee	6.00%
Vesting period	4 years
Contribution amount | $	$ 0.1	$ 0.1

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	Feb. 11, 2021	Feb. 28, 2021	Jan. 31, 2021	Jan. 01, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
April 2020 Note Purchase Agreement
Subsequent Event [Line Items]
Conversion of convertible note, amount					$ 2,000,000	$ 2,000,000
Conversion of convertible note exchanged for shares					322,348	316,461
2014 Equity Incentive Plan
Subsequent Event [Line Items]
Share-based compensation arrangement by share-based payment award, number of additional shares authorized							389,650	191,887
2014 Employee Stock Purchase Plan
Subsequent Event [Line Items]
Share-based compensation arrangement by share-based payment award, number of additional shares authorized							2,941	2,941
Subsequent Event | Amplity Inc.
Subsequent Event [Line Items]
Term of agreement		5 years
Subsequent Event | Exclusive License and Collaboration Agreement
Subsequent Event [Line Items]
Upfront payment received	$ 10,000,000
Subsequent Event | Exclusive License and Collaboration Agreement | Maximum
Subsequent Event [Line Items]
Development and commercial milestones received	$ 112,000,000
Subsequent Event | April 2020 Note Purchase Agreement
Subsequent Event [Line Items]
Conversion of convertible note, amount			$ 6,000,000
Conversion of convertible note exchanged for shares			959,080
Subsequent Event | 2014 Equity Incentive Plan
Subsequent Event [Line Items]
Share-based compensation arrangement by share-based payment award, number of additional shares authorized				786,547
Subsequent Event | 2014 Employee Stock Purchase Plan
Subsequent Event [Line Items]
Share-based compensation arrangement by share-based payment award, number of additional shares authorized				2,941